1-Methoxypentadecan | 7307-52-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Methoxypentadecan
• 英文别名: 1-methoxy-pentadecane；1-Methoxypentadecane
• CAS: 7307-52-0
• 化学式: C₁₆H₃₄O
• 分子量: 242.445
• InChiKey: QTAFOTOCTOIEKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  17
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  甲醇 、 1-Methoxypentadecan 生成 methyl 14-hydroxypentadecanoate
  参考文献：
  名称：

  长链脂族化合物的微生物氧化。第三部分 1-卤代烷烃，1-氰基十六烷和1-烷氧基烷烃

  摘要：

  在含有葡萄糖的培养基中，灰鹤菌酵母进行以下转化：（a）将长链1-卤代烷烃转变为αω-链烷二酸；（a）将长链1-卤代烷烃转化为αω-链烷二酸；（b）1-氰基十六烷为16-氧代十六烷酸的氰醇衍生物；（c）长链的1-甲氧基烷烃和1-乙氧基烷烃成ω-羟基链烷酸；（d）长链的1-丙氧基烷烃为ω-和ω-1-羟基烷氧基链烷酸。转化产物作为糖脂与培养基分离。提出了解释这些转化的代谢途径。

  DOI：

  10.1039/j39680002816

文献信息

• Process for Preparation of Hexadecyl Cis-9-Tetradecenoate and Hexadecyl Cis-10-Tetradecenoate
  申请人：Bethala Lakshmi Anu Prabhavathi Devi

  公开号：US20110269987A1

  公开（公告）日：2011-11-03

  Hexadecyl cis-9-tetradecenoate commonly known as Cetyl myristoleate (CMO) is being used for the treatment of osteoarthritis and other joint inflammatory diseases, cis-9-Tetradecenoic acid (cis-9-myristoleic acid) is the main precursor for the preparation of CMO. As there are limited natural plant sources for cis-9-tetradecenoic acid, the present invention aimed at the synthesis of cis-9-tetradecenoic acid methyl ester from oleic acid methyl ester. As oleic acid is not available in pure form, this has to be isolated from oleic acid-rich oils like olive oil. cis-10-Tetradecenoic acid methyl ester, an isomer of cis-9-tetradecenoic acid was also prepared from undecenoic acid methyl ester, a derivative of castor oil. Undecenoic acid is easily available commercially in pure form. Hexadecyl cis-9-tetradecenoate and hexadecyl c/s-10-tetradecenoate were prepared by enzymatic transesterification of cis-9-tetradecenoic acid methyl ester and cis-10-tetradecenoic acid methyl ester with 1-hexadecanol (cetyl alcohol) respectively. Both the isomers of cetyl myristoleate were evaluated for anti arthritis, blocking inflammation and reduction of adjuvant-induced arthritis in rats.

  十六烷基顺-9-十四碳烯酸盐通常被称为鲸蜡醇豆蔻酸酯（CMO），目前正被用于治疗骨关节炎和其他关节炎症疾病，顺-9-十四碳烯酸（顺-9-豆蔻酸）是制备CMO的主要前体。由于顺-9-十四碳烯酸的自然植物来源有限，本发明旨在从油酸甲酯合成顺-9-十四碳烯酸甲酯。由于油酸无法以纯净形式获得，因此需要从富含油酸的油类如橄榄油中提取。还从十一烯酸甲酯，即蓖麻油的衍生物，制备了顺-10-十四碳烯酸甲酯，这是顺-9-十四碳烯酸的异构体。十一烯酸在市场上容易以纯净形式获得。通过酶促转酯反应，分别用顺-9-十四碳烯酸甲酯和顺-10-十四碳烯酸甲酯与1-十六醇（鲸蜡醇）反应，制备了十六烷基顺-9-十四碳烯酸盐和十六烷基顺-10-十四碳烯酸盐。这两种鲸蜡醇豆蔻酸酯的异构体都进行了抗关节炎、阻断炎症和在大鼠中减少佐剂诱导关节炎的评价。
• ISOCYANATE PRODUCTION PROCESS
  申请人：Shinohata Masaaki

  公开号：US20110092731A1

  公开（公告）日：2011-04-21

  An object of the present invention is to provide a process that enables isocyanate to be produced stably over a long period of time and at high yield without encountering problems of the prior art during production of isocyanate without using phosgene. The present invention discloses a process for producing an isocyanate by subjecting a carbamic acid ester to a thermal decomposition reaction, including the steps of: recovering a low boiling point component in a form of a gaseous phase component from a thermal decomposition reaction vessel in which the thermal decomposition reaction is carried out; recovering a liquid phase component containing a carbamic acid ester from a bottom of the thermal decomposition reaction vessel; and supplying all or a portion of the liquid phase component to an upper portion of the thermal decomposition reaction vessel.

  本发明的一个目的是提供一种能够在长时间内稳定地高产且不使用光气的情况下生产异氰酸酯的方法，而不会遇到先前生产异氰酸酯时的问题。本发明公开了一种通过将氨基甲酸酯经受热分解反应来生产异氰酸酯的方法，包括以下步骤：从进行热分解反应的反应釜中回收形成气相组分的低沸点组分；从热分解反应釜底部回收含有氨基甲酸酯的液相组分；并将全部或部分液相组分供给至热分解反应釜的上部。
• Amino alcohol derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030236297A1

  公开（公告）日：2003-12-25

  Compounds of formula (I) which exhibit excellent immune suppression activity, pharmacologically acceptable salts thereof, esters thereof or other derivatives: 1 wherein R 1 and R 2 are a hydrogen atom, an amino protecting group; R 3 is a hydrogen atom, a hydroxy protecting group; R 4 is a lower alkyl group; n is an integer from 1 to 6; X is an ethylene group; Y is a C 1 -C 10 alkylene group, a C 1 -C 10 alkylene group substituted with 1 to 3 substituents selected from substituent group a and b; R 5 is an aryl group; R 6 and R 7 are a hydrogen atom, a group selected from substituent group a; with the proviso when R 5 is a hydrogen atom, Y is not a single bond or a straight chain C 1 -C 10 alkylene group.

  式（I）的化合物表现出优异的免疫抑制活性，其药理学上可接受的盐，酯或其他衍生物：其中R1和R2是氢原子，氨基保护基；R3是氢原子，羟基保护基；R4是较低的烷基基团；n是1到6之间的整数；X是乙烯基团；Y是C1-C10烷基基团，带有1到3个从取代基a和b中选择的取代基的C1-C10烷基基团；R5是芳基基团；R6和R7是氢原子，从取代基a中选择的基团；但是当R5是氢原子时，Y不是单键或直链的C1-C10烷基基团。
• Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
  申请人：Nishi Takahide

  公开号：US20050043386A1

  公开（公告）日：2005-02-24

  Amino alcohol compounds and phosphonic acid compounds having excellent immunosuppressive activity, pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof, and pharmaceutical compositions comprising such compounds, the compounds having the following formula: wherein R 1 and R 2 each represent hydrogen, or a protecting group of the amino group; R 3 represents hydrogen, or a protecting group of the hydroxyl group; R 4 represents a lower alkyl group; n is 1 to 6; X represents oxygen or nitrogen, which is unsubstituted or substituted with a lower alkyl group; Y represents ethylene; Z represents a C 1 -C 10 alkylene; R 5 represents an aryl group; and R 6 and R 7 each represents hydrogen; provided that when R 5 represents hydrogen, then Z represents a group other than a single bond or a straight chain C 1 -C 10 alkylene group.

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。
• Amino alcohol compounds
  申请人：Nishi Takahide

  公开号：US20070105933A1

  公开（公告）日：2007-05-10

  A method for the preventing a disease selected from the group consisting of rheumatoid arthritis and psoriasis in a mammal, such as a human, in need thereof, which includes administering to the mammal a pharmaceutically effective amount of a compound of formula (Ia) wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is=N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  本发明涉及一种用于预防哺乳动物，例如人类，需要预防风湿性关节炎和银屑病等疾病的方法，包括向哺乳动物内部给予化合物（Ia）的药物有效量，其中R1和R2均为氢; R3为氢; R4为C1-C2烷基; n为2; X为=N-D，其中D为氢、C1-C4烷基或苯基; Y为乙烯基、乙炔基、-CO-CH2或苯基; Z为乙烯基或三亚甲基; R5为未取代的C3-C10环烷基、未取代的C6-C10芳基或取代有1-3个取代基的C3-C10环烷基或C6-C10芳基，所述取代基选自卤素、低碳基、卤代低碳基和低烷氧基的群体; R6和R7均为氢。